- Home
- NMRK vs MESO Comparison
NMRK vs MESO Comparison
Compare NMRK & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | MESO |
|---|---|---|
| Founded | 1929 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NMRK | MESO |
|---|---|---|
| Price | $10.64 | $13.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $16.75 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.2M | 257.5K |
| Earning Date | 10-29-2026 | 08-26-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $3,294,024,000.00 | N/A |
| Revenue This Year | $14.47 | $51.63 |
| Revenue Next Year | $4.78 | $63.39 |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $10.84 | $11.89 |
| 52 Week High | $18.25 | $21.50 |
Technical Indicators
Market Signals| Indicator | NMRK | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 34.13 | 43.23 |
| Support Level | N/A | $11.89 |
| Resistance Level | $16.13 | $16.03 |
| Average True Range (ATR) | 0.52 | 0.54 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 1.72 | 10.88 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.